Antiretroviral News and Research

RSS

Increasing risk of HIV among seniors

People ages 50 and older are more likely to have unprotected sex than younger groups, increasing their risk for HIV and other sexually transmitted infections, according to a recently released World Health Organization study, Reuters UK reports.

4 Mar 2009

Hair helps predicts HIV antiretroviral treatment success

UCSF researchers have found that examining levels of antiretroviral drugs in hair samples taken from HIV patients on therapy strongly predicts treatment success.

3 Mar 2009

A new monkey model for HIV

By altering just one gene in HIV-1, scientists have succeeded in infecting pig-tailed macaque monkeys with a human version of the virus that has until now been impossible to study directly in animals.

2 Mar 2009

Mylan's Matrix receives WHO approval for generic Lopinavir/Ritonavir tablets

Mylan Inc. has announced that Matrix Laboratories Limited, its India-based subsidiary in which it holds a 71.5% controlling interest, received the first and only World Health Organization (WHO) approval for Lopinavir/Ritonavir Tablets, 200 mg/50 mg. Matrix's version of this product is heat-stable and affordable, making it practical for distribution and use in warm climates.

25 Feb 2009

Study finds major interruptions in antiretroviral therapy after release from prison

The vast majority of HIV-infected Texas prison inmates who receive antiretroviral therapy while incarcerated experience significant interruptions in HIV treatment after their release into the community.

24 Feb 2009

Gene therapy shows potential against HIV

A new UCLA AIDS Institute study has found that gene therapy can be developed as a safe and active technique to combat HIV.

22 Feb 2009

Anti-HIV vaginal gel shows promise

An investigational vaginal gel intended to prevent HIV infection in women has demonstrated encouraging signs of success in a clinical trial conducted in Africa and the United States.

9 Feb 2009

Sangamo BioSciences starts trial of CCR5-ZFP therapeutic to treat HIV/AIDS

Sangamo BioSciences, Inc. has announced that its collaborators at the University of Pennsylvania have opened a Phase 1 clinical trial to evaluate SB-728-T for the treatment of HIV/AIDS.

5 Feb 2009

New study sheds light on higher adherence to HIV drugs in Africa than in North America

Levels of near-perfect adherence to life saving antiretroviral drugs among African HIV patients should be understood as a means of preserving key social relationships, says a new study published in the open-access journal PLoS Medicine.

27 Jan 2009

Kidney transplant survival can be long-term for people with HIV

A Johns Hopkins study finds that HIV-positive kidney transplant recipients could have the same one-year survival rates for themselves and their donor organs as those without HIV, provided certain risk factors for transplant failure are recognized and tightly managed.

19 Jan 2009

Mutant host cell protein sequesters critical HIV-1 element

Scientists have identified a new way to inhibit a molecule that is critical for HIV pathogenesis.

19 Jan 2009

Prolonged nevirapine in breast-fed babies prevents HIV infection but leads to drug-resistant HIV

Babies born to HIV-positive mothers and given the antiretroviral drug nevirapine through the first six weeks of life to prevent infection via breast-feeding are at high risk for developing drug-resistant HIV if they get infected anyway, a team of researchers report.

5 Jan 2009

Final FDA approval for generic version of antiretroviral Zerit capsules

Mylan Inc. has announced that Matrix Laboratories Limited, its India-based subsidiary in which it holds a 71.5% controlling interest, received final approval from the U.S. Food and Drug Administration (FDA) on December 29, for its Abbreviated New Drug Application (ANDA) for Stavudine Capsules USP, 15 mg, 20 mg, 30 mg and 40 mg.

1 Jan 2009

Roche's new dual-target HIV-1 test approved in Europe

Roche announced today that its innovative dual-target HIV-1 test has received CE Mark certification, allowing it to be sold for clinical use in the European Union. The COBAS AmpliPrep/COBAS TaqMan HIV-1 Test, v2.0 utilizes a unique design to simultaneously amplify and detect two separate regions of the HIV-1 genome.

15 Dec 2008

Well-armed immune cells help long-term non-progressors contain HIV

To help develop an effective HIV vaccine, researchers are trying to better understand how the immune systems of a small minority of HIV-infected people known as long-term non-progressors (LTNPs) contain the virus naturally.

5 Dec 2008

New insights into development of the human immune system

A UCSF study has found that a surprisingly high number of maternal cells enters the fetus during pregnancy, prompting the generation of special immune cells in the fetus that suppress a response against the mother.

5 Dec 2008

Extraordinary immune cells may hold the key to managing HIV

People who manage to control HIV on their own are providing scientists with valuable information about how the immune system eliminates virus-infected cells.

5 Dec 2008

WHO boss says major milestone reached in fight against AIDS

Dr. Margaret Chan, WHO Director-General says a major milestone in the long struggle against HIV/AIDS has been reached.

3 Dec 2008

20th anniversary of World AIDS day - experts say universal, voluntary testing could reduce new HIV cases by 95%

December the 1st 2008 marked the 20th anniversary of World AIDS day - a day when people around the world take stock of the AIDS situation and consider those who have died from the disease and those who are struggling to live with it.

1 Dec 2008

Universal voluntary testing, immediate treatment can reduce new HIV cases by 95% within 10 years

Universal and annual voluntary testing followed by immediate antiretroviral therapy treatment (irrespective of clinical stage or CD4 count) can reduce new HIV cases by 95% within 10 years, according to new findings based on a mathematical model developed by a group of HIV specialists in WHO.

26 Nov 2008